Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia · Delayed Price · Currency is MYR 1.280
-0.020 (-1.54%)
At close: Aug 28, 2026
Duopharma Biotech Berhad Income Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 929.41 | 931.69 | 813.7 | 704.73 | 696.72 | 639.18 | |
Revenue Growth | 4.79% | 14.50% | 15.46% | 1.15% | 9.00% | 12.16% |
Cost of Revenue | 545.85 | 568.56 | 512.16 | 436.4 | 416.9 | 385.19 |
Gross Profit | 383.56 | 363.14 | 301.54 | 268.33 | 279.82 | 253.98 |
Selling, General & Admin | 228.63 | 226.65 | 202.02 | 182.72 | 186.59 | 165.78 |
Other Operating Expenses | 2.41 | 2.17 | 0.7 | 2.8 | 0.81 | -0.67 |
Operating Expenses | 231.57 | 229.36 | 201.28 | 189.61 | 186.91 | 165.22 |
Operating Income | 151.99 | 133.78 | 100.26 | 78.71 | 92.91 | 88.77 |
Interest Expense | -23.09 | -24.16 | -25.77 | -17.68 | -9.1 | -6.44 |
Interest & Investment Income | 5.97 | 5.87 | 5.97 | 2.75 | 1.52 | 1.2 |
Other Non Operating Income (Expenses) | -0.59 | -0.59 | -0.82 | -0.52 | -0.48 | -0.53 |
EBT Excluding Unusual Items | 134.29 | 114.9 | 79.63 | 63.27 | 84.85 | 82.99 |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | 0.39 | - | - | -0.01 |
Pretax Income | 134.3 | 114.91 | 80.02 | 63.27 | 84.85 | 82.98 |
Income Tax Expense | 32.09 | 27.45 | 17.38 | 10.62 | 14.74 | 17.3 |
Net Income | 102.21 | 87.46 | 62.65 | 52.65 | 70.11 | 65.68 |
Net Income to Common | 102.21 | 87.46 | 62.65 | 52.65 | 70.11 | 65.68 |
Net Income Growth | 33.56% | 39.62% | 19.00% | -24.91% | 6.74% | 12.07% |
Shares Outstanding (Basic) | 962 | 962 | 962 | 959 | 948 | 928 |
Shares Outstanding (Diluted) | 962 | 962 | 962 | 959 | 948 | 928 |
Shares Change | 0.14% | - | 0.36% | 1.08% | 2.15% | 0.02% |
EPS (Basic) | 0.11 | 0.09 | 0.07 | 0.05 | 0.07 | 0.07 |
EPS (Diluted) | 0.11 | 0.09 | 0.07 | 0.05 | 0.07 | 0.07 |
EPS Growth | 33.38% | 39.62% | 18.57% | -25.71% | 4.50% | 12.05% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 64.52 | 79.99 | 59.77 | 15.86 | 5.08 | -66.16 |
Free Cash Flow Per Share | 0.07 | 0.08 | 0.06 | 0.02 | 0.01 | -0.07 |
Dividend Per Share | 0.045 | 0.045 | 0.030 | 0.023 | 0.023 | 0.022 |
Dividend Growth | 30.00% | 51.67% | 30.44% | 0% | 5.75% | -55.43% |
Gross Margin | 41.27% | 38.98% | 37.06% | 38.07% | 40.16% | 39.74% |
Operating Margin | 16.35% | 14.36% | 12.32% | 11.17% | 13.33% | 13.89% |
Profit Margin | 11.00% | 9.39% | 7.70% | 7.47% | 10.06% | 10.28% |
Free Cash Flow Margin | 6.94% | 8.59% | 7.35% | 2.25% | 0.73% | -10.35% |
EBITDA | 188.53 | 171.05 | 137.34 | 114.04 | 122.86 | 114.94 |
EBITDA Margin | 20.29% | 18.36% | 16.88% | 16.18% | 17.63% | 17.98% |
D&A For EBITDA | 36.54 | 37.27 | 37.08 | 35.32 | 29.95 | 26.18 |
EBIT | 151.99 | 133.78 | 100.26 | 78.71 | 92.91 | 88.77 |
EBIT Margin | 16.35% | 14.36% | 12.32% | 11.17% | 13.33% | 13.89% |
Effective Tax Rate | 23.90% | 23.89% | 21.72% | 16.79% | 17.37% | 20.85% |